Chiu HY, Chiu YM, Liao NFC, et al. - In patients with psoriasis receiving biologics, researchers determined the predictors of hepatitis B (HBV) and C virus (HCV) reactivation. Two thousand sixty psoriasis patients (3,562 treatment episodes) who were taking biologics from 2009 to 2018 were screened in this analysis. There were 359 HBV patients with psoriasis (561 treatment episodes) and 61 with HCV infection (112 treatment episodes). Eighty-eight treatment episodes for HBV involved HBV reactivation and 14 episodes of HCV involved reactivation during 8,809 and 1,522 person-months of follow-up. According to findings, patients with psoriasis on biologics have a risk of HBV and HCV reactivations, especially those who are HBsAg-seropositive, HBeAg-seropositive, and undergoing TNF-α inhibitor therapy. No predictors were significantly linked to HCV reactivation.